Novo slumps, Lilly gains on trial data results

Novo slumps, Lilly gains on trial data results

Investing.com — Shares of Novo Nordisk (NYSE:NVO) plummeted over 19% in premarket trading Friday after the results from its phase 3 trial of CagriSema, its next-generation obesity drug, disappointed. Meanwhile, rival…
Factbox-Swiss findings on the Credit Suisse collapse

Factbox-Swiss findings on the Credit Suisse collapse

ZURICH (Reuters) – Switzerland on Friday published a long-awaited parliamentary report into last year’s collapse of Credit Suisse, an event that called into question the country’s reputation for financial stability…